HCI-044-EI breast cancer PDX

HCI-044-EI PDX – Sample taken in 2018 from brain met of Caucasian female, age 43 at time of collection with a primary diagnosis of IDC; 2014 (stage IV with bone mets only).

Contributors

Inventor Institute
Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose The University of Utah Research Foundation
SKU: 162111
Product description: HCI-044-EI PDX – Sample taken in 2018 from brain met of Caucasian female, age 43 at time of collection with a primary diagnosis of IDC; 2014 (stage IV with bone mets only).
Cat. #: 162111
Cancer types: Breast cancer
Gender: Female
Biopsy Site: Brain metastasis
Patient ethnicity: Caucasian
Treatment History: Pretreated: Patient had undergone radiation therapy to the hip 2014; skull and mandible 2015; sacrum and S2 2018 and had received systemic treatment of denosumab 2014; add tamoxifen 2015; taxol 2015; exemestane 2015-2017; tamoxifen 2017; letrozole, palbociclib 2017-2018; doxorubicin 2018 prior to sample collection
Primary citation: Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336
Initial handling information: Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice NSG. NSG (fresh) time to growth: 5 months to 2 cm. Positive ER status
Additional notes: Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9
Mice Passaged: Yes
Engraftment Site: Cleared mammary fat pad
Host Strain: Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799
Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.
References:

Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946

Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637

Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007

Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602

Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134

Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336

Related Tools for PDX models

Cat. # Tool Name
151156 Anti-Rb1 [Rb1 (1F8)] Key Info View Tool
152698 Anti-PALB2 [M41-P3F3] Key Info View Tool
162069 HCI-001 breast cancer PDX Key Info View Tool
162074 HCI-006 breast cancer PDX Key Info View Tool
162077 HCI-009 breast cancer PDX Key Info View Tool

Related News

Representative example of haematoxylin and eosin staining of CRUK0935 T1-R5 TRACERx lung cancer PDX model at early P0 passage.
PDX Models

New non-small cell lung cancer (NSCLC) patient-derived-xenograft (PDX) models now available at CancerTools.org

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.